The acquisition, which took the global contract development and manufacturing organization private, is a one-off the likes of which the industry will not see again.
While the two companies dominate the market, Celltrion’s strong presence in deal-making is driving South Korea’s growing influence in the global biosimilars landscape.
Designed to produce 20 billion capsules annually, the new 175,000-square-meter facility leverages technology to enhance product quality and supply chain efficiency.
